SCHEMBL6523191

SCHEMBL6523191

COc1ccc2c(c1)/C(=C\c1ccc3c(C=Cc4ccc(C(=O)O)cc4)n[nH]c3c1)C(=O)N2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FCER2 P06734 1/20 0.49
SYK P43405 1/20 0.49
LRRK2 Q5S007 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
RET P07949 5/20 0.46
TLK2 Q86UE8 4/20 0.46
PIM1 P11309 2/20 0.44
KDR P35968 3/20 0.44
CDK2 P24941 3/20 0.44
AURKB Q96GD4 3/20 0.44
CDK1 P06493 2/20 0.44
MAPK1 P28482 2/20 0.44
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
CDK7 P50613 2/20 0.44
CDK9 P50750 2/20 0.44
CDK5 Q00535 2/20 0.44
CHEK1 O14757 2/20 0.44
PDPK1 O15530 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523186 1.00 FCER2 (0.49) FCER2SYKLRRK2MEN1KMT2A
SCHEMBL6523194 1.00 FCER2 (0.49) FCER2SYKLRRK2MEN1KMT2A
SCHEMBL12795416 0.92 PSEN1 (0.51) FCER2SYKLRRK2RETTLK2
SCHEMBL3798538 0.88 CDK2 (0.50) LRRK2RETTLK2PIM1KDR
SCHEMBL6519110 0.88 LRRK2 (0.51) FCER2SYKLRRK2RETTLK2
SCHEMBL3798541 0.88 CDK2 (0.50) LRRK2RETTLK2PIM1KDR
SCHEMBL6519115 0.88 LRRK2 (0.51) FCER2SYKLRRK2RETTLK2
SCHEMBL6519117 0.88 LRRK2 (0.51) FCER2SYKLRRK2RETTLK2
SCHEMBL6525456 0.86 PIM1 (0.62) MEN1KMT2ARETPIM1KDR
SCHEMBL6525459 0.86 PIM1 (0.62) MEN1KMT2ARETPIM1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 FCER2 3992/4885SYK 193/4885LRRK2 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.